过氧化物酶体增殖物激活受体γ抑制肝癌细胞的增殖生长和侵袭转移

沈波; 聂玉强

doi:10.3969/j.issn.1001-5256.2013.09.018

过氧化物酶体增殖物激活受体γ抑制肝癌细胞的增殖生长和侵袭转移

DOI: 10.3969/j.issn.1001-5256.2013.09.018

沈波,
聂玉强

广州市第一人民医院消化内科

基金项目:

2010国家青年科学基金项目资助(30900665)； 2012国家自然基金资助(81270037)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3151
- HTML全文浏览量: 16
- PDF下载量: 630
- 被引次数: 0
出版历程
- 收稿日期: 2012-12-08
- 出版日期: 2013-09-20

Peroxisome proliferator- activated receptor gamma inhibits liver cancer proliferation and metastasis in vitro

Department of Gastroenterology, Guangzhou First People's Hospital

Research funding:

摘要

摘要:
目的检测过氧化物酶体增殖物激活受体（PPAR）γ对肝癌的发生发展和侵袭转移的抑制作用。方法培养肝癌细胞MHCC97L,以携带PPARγ腺病毒（Ad-PPARγ）为载体使PPARγ在肝癌细胞内高表达,联合PPARγ激动剂罗格列酮治疗,运用MTS、流式细胞仪、细胞伤口愈合及基质胶侵袭试验检测PPARγ对肝癌细胞增殖、调亡和运动侵袭能力的影响。多个样本均数间的比较用单因素方差Bonferroni校正法分析。两组样本均数比较用t检验。结果相对于对照组,Ad-PPARγ使肝癌细胞高表达PPARγ,进而显著抑制细胞的增殖活力（P<0.01）,诱导细胞凋亡（P<0.01）,削弱细胞迁移和侵袭能力（下降20%60%）。AdPPARγ和罗格列酮对抑制肝癌细胞增长和转移具有联合效益。结论 PPARγ对肝癌细胞的增殖生长和侵袭转移有抑制作用,本研究为临床寻找可能的肝癌标志物和基因治疗提供了新思路和理论基础。
- PPARγ /
- 癌,肝细胞 /
- 肿瘤侵润 /
- 细胞凋亡 /
- 细胞增殖
Abstract:
Objective To investigate the inhibitory effect of peroxisome proliferator- activated receptor gamma ( PPARγ) on the development, progression, invasion, and metastasis of liver cancer cells. Methods Hepatocellular carcinoma ( HCC) MHCC97L cells were randomly assigned to be transfected with Ad- PPARγ or Ad- LacZ ( control) . The cells were also exposed to PPARγ agonist rosiglitazone. Cell proliferation, apoptosis, migration, and invasive ability were evaluated using MTS assay, flow cytometry, wound healing test, and transwell invasion assay. Multiple comparisons of means between groups were conducted using one- way analysis of variance with Bonferroni correction; the means of two groups were compared using the t test. Results Ad- PPARγ transfection resulted in higher expression of PPARγprotein in HCC cells compared with control cells, which suppressed cell proliferation ( P < 0. 01) , induced cell apoptosis ( P < 0. 01) , and suppressed cell migration and invasion. Moreover, the invasiveness of HCC cells transfected with Ad- PPARγ was reduced by 20% ~ 60%.Rosiglitazone enhanced the inhibitory effect of Ad- PPARγ on the growth and migration of HCC cells. Conclusion PPARγ exerts an inhibitory effect on the proliferative, invasive, and metastatic potential of HCC cells in vitro. This study sheds new light on the search for potential markers and gene therapies for liver cancer.
- PPAR gamma /
- carcinoma, hepatocellular /
- neoplasm invasiveness /
- apoptosis /
- cell proliferation

HTML全文

参考文献(15)

[1]BOCCA C, BOZZO F, FRANCICA S, et al.Involvement of PPAR gamma and E-cadherin/beta-catenin pathway in the antiproliferative effect of conjugated linoleic acid in MCF-7 cells[J].Int J Cancer, 2007, 121 (2) :248-256.

[2]CERBONE A, TOALDO C, LAURORA S, et al.4-Hydroxynonenal and PPARgamma ligands affect proliferation, differentiation, apoptosis in colon cancer cells[J].Free Radic Biol Med, 2007, 42 (11) :1661-1670.

[3]LI M, LEE TW, MOK TS, et al.Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth[J].J Cell Biochem, 2005, 96 (4) :760-774.

[4]JARRAR MH, BARANOVA A.PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome:the importance of interplay with TGFbeta signalling[J].J Cell Mol Med, 2007, 11 (1) :71-87.

[5]PAN HF, CHEN XP.Influence of Ciglitazone on hepatic cancer cells HepG2 growth in vitro and in vivo and its mechanisms[J].Chin J Exp Surg, 2004, 21 (8) :934-936. (in Chinese) 潘华锋, 陈孝平.Ciglitazone抑制人肝癌HepG2细胞增殖活性的实验研究[J].中华实验外科杂志, 2004, 21 (8) :934-936.

[6]LI MY, DENG H, ZHAO JM, et al.Effect of peroxisome proliferator-activated receptor gamma ligands on cell cycle kinetics in BEL-7402 liver cancer cells[J].Chin J Exp Surg, 2004, 21 (2) :150-151. (in Chinese) 李明意, 邓华, 赵家明, 等.过氧物酶体增殖因子活化受体γ配体对人肝癌细胞系BEL-7402细胞周期的影响[J].中华实验外科杂志, 2004, 21 (2) :150-151.

[7]GUO YT, LENG XS, ZHAO JM, et al.Pexoxisome proliferatoractivated receptor gamma ligands suppress liver carcinogenesis induced by diethlnitrosamine in rats[J].Chin J Hepatol, 2005, 13 (2) :145-146. (in Chinese) 郭晏同, 冷希圣, 赵景明, 等.过氧化物酶体增殖物激活化受体γ配体对诱导大鼠肝癌的抑制作用[J].中华肝脏病杂志, 2005, 13 (2) :145-146.

[8]YU J, QIAO L, ZIMMERMANN L, et al.Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo[J].Hepatology, 2006, 43 (1) :134-143.

[9]MUELLER E, SARRAF P, TONTONOZ P, et al.Terminal differentiation of human breast cancer through PPAR gamma[J].Mol Cell, 1998, 1 (3) :465-470.

[10]BOGAZZI F, ULTIMIERI F, RAGGI F, et al.Changes in the expression of the peroxisome proliferator-activated receptor gamma gene in the colonic polyps and colonic mucosa of 27 acromegalic patients[J].J Clin Endocrinol Metab, 2003, 88 (8) :3938-3942.

[11]YU J, SHEN B, CHU ES, et al.Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro[J].Hepatology, 2010, 51 (6) :2008-2019.

[12]EVAN GI, VOUSDEN KH.Proliferation, cell cycle and apoptosis in cancer[J].Nature, 2001, 411 (6835) :342-348.

[13]TAKANO S, KUBOTA T, NISHIBORI H, et al.Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis[J].Anticancer Res, 2008, 28 (6A) :3593-3599.

[14]CHEN Y, WANG SM, WU JC, et al.Effects of PPARgamma agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line[J].J Cell Biochem, 2006, 98 (4) :1021-1035.

[15]PANIGRAHY D, SINGER S, SHEN LQ, et al.PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis[J].J Clin Invest, 2002, 110 (7) :923-932.

施引文献

资源附件(0)

访问统计